Myovant Sciences and Pfizer Present Data on Relugolix

BASEL, Switzerland and NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced the...

Related Keywords

United States ,Switzerland ,American ,James Rusnak ,Juan Camilo Arjona Ferreira ,Uterine Fibroids Scientific Congress Prize Paper ,Linkedin ,Pfizer ,Pfizer Inc ,Endometriosis Health Profile ,Myovant Sciences Forward ,Effect On Other Laboratory ,American Society For Reproductive Medicine ,Myovant Sciences ,Drug Administration ,European Commission ,Global Product Development ,Exchange Commission ,Youtube ,Myovant Sciences Inc ,Sumitomo Dainippon Pharma Co Ltd ,Sumitovant Biopharma Ltd ,American Society ,Reproductive Medicine ,Chief Medical Officer ,Senior Vice President ,Chief Development Officer ,Internal Medicine ,Withdrawal Study ,Year Efficacy ,Relugolix Combination Therapy ,Heavy Menstrual Bleeding Associated ,Uterine Fibroids ,Scientific Congress Prize Paper ,New Drug Application ,Boxed Warning ,Sensitive Malignancies ,Mood Disorders ,Suicidal Ideation ,Transaminase Elevations ,Cholestatic Jaundice ,Blood Pressure ,Menstrual Bleeding Pattern ,Reduced Ability ,Recognize Pregnancy ,Early Pregnancy Loss ,Fibroid Prolapse ,Lipid Metabolism ,Sumitovant Biopharma ,Breakthroughs That Change Patient Lives ,Pfizer News ,Private Securities Litigation Reform Act ,Myovant Science ,United States Securities ,Myovant Science Quarterly Report ,Nyse Myov ,Nc ,Myovant ,Healthcare ,